ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Mylan Buys Famy Care, Licenses Lung Drug

by Lisa M. Jarvis
February 9, 2015 | APPEARED IN VOLUME 93, ISSUE 6

Specialty drug company Mylan is shelling out $750 million to buy several female health care businesses from Mumbai-based Famy Care. Famy, a leader in generic oral contraceptives, has been a marketing partner of Mylan since 2008. In a separate deal, Mylan will pay Theravance Biopharma $15 mil­lion for access to TD-4208, a treatment for chronic obstructive pulmonary disease. Theravance expects to begin Phase III studies on TD-4208, a once-daily nebulized muscarinic antagonist, this year. Mylan is also taking a $30 million stake in the biotech firm.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment